1. Home
  2. RDVT vs ALLO Comparison

RDVT vs ALLO Comparison

Compare RDVT & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Red Violet Inc.

RDVT

Red Violet Inc.

HOLD

Current Price

$35.26

Market Cap

527.9M

Sector

Technology

ML Signal

HOLD

Logo Allogene Therapeutics Inc.

ALLO

Allogene Therapeutics Inc.

HOLD

Current Price

$2.27

Market Cap

539.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RDVT
ALLO
Founded
2017
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
527.9M
539.4M
IPO Year
2017
2018

Fundamental Metrics

Financial Performance
Metric
RDVT
ALLO
Price
$35.26
$2.27
Analyst Decision
Strong Buy
Buy
Analyst Count
1
11
Target Price
$62.00
$8.40
AVG Volume (30 Days)
107.6K
4.5M
Earning Date
03-04-2026
03-12-2026
Dividend Yield
N/A
N/A
EPS Growth
82.00
34.09
EPS
0.91
N/A
Revenue
$90,252,000.00
N/A
Revenue This Year
$15.06
N/A
Revenue Next Year
$15.07
$140,929.80
P/E Ratio
$39.87
N/A
Revenue Growth
20.03
N/A
52 Week Low
$32.23
$0.86
52 Week High
$64.14
$2.80

Technical Indicators

Market Signals
Indicator
RDVT
ALLO
Relative Strength Index (RSI) 30.13 49.90
Support Level N/A $2.14
Resistance Level $52.43 $2.76
Average True Range (ATR) 2.06 0.22
MACD -0.42 -0.04
Stochastic Oscillator 6.28 30.30

Price Performance

Historical Comparison
RDVT
ALLO

About RDVT Red Violet Inc.

Red Violet Inc builds proprietary technologies and applies analytical capabilities to deliver identity intelligence. The company's solutions enable the real-time identification and location of people, businesses, assets, and their interrelationships. These solutions are used for purposes including identity verification, risk mitigation, due diligence, fraud detection and prevention, regulatory compliance, and customer acquisition. Its cloud-native, AI-enabled identity intelligence platform, CORE, is purpose-built for the enterprise, yet flexible enough for organizations of all sizes, bringing clarity to massive datasets by transforming data into intelligence. The company generates substantially all of its revenue from licensing its solutions.

About ALLO Allogene Therapeutics Inc.

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.

Share on Social Networks: